GPP
WVE icon

Great Point Partners’s Wave Life Sciences WVE Stock Holding History

Great Point Partners’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-331,085
Closed -$11.6M – 44
2017
Q4 		$11.6M Buy
+331,085
New +$9.65M 1.98% 22

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Great Point Partners's WVE Position: Q1 2018 in Review

Great Point Partners sold out of Wave Life Sciences (WVE) in Q1 2018, closing a stake of 331,085 shares — an estimated $11.6M sold.

Great Point Partners first reported a position in WVE in Q4 2017 and held it in 1 quarter. The position peaked at $11.6M in Q4 2017. 79 funds tracked by Wall St. Rank hold WVE as of Q1 2018.

  • Great Point Partners reported no remaining Wave Life Sciences position as of Q1 2018 after selling out during the quarter.
  • Great Point Partners sold 331,085 Wave Life Sciences shares in Q1 2018, an estimated $11.6M.
  • Great Point Partners first reported a position in Wave Life Sciences in Q4 2017 and held it in 1 quarter.
  • Great Point Partners's Wave Life Sciences position peaked at $11.6M in Q4 2017.
  • 79 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2018.

Based on Great Point Partners's 13F filing for Q1 2018, filed 14 May 2018.